radiation syndrome


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.

radiation syndrome

radiation sickness

The generic term for the constellation of findings associated with exposure to high doses of ionising radiation.

radiation syndrome

Any condition induced by radiation Examples Radiation arthropathy, radiation carditis, radiation cytitis, radiation dermatitis, radiation enteropathy, radiation fibrosis, radiation hepatitis, radiation nephritis, radiation pneumonitis. See Radiation enteropathy, Radiation pneumonitis.

ra·di·a·tion syn·drome

(rā'dē-ā'shŭn sin'drōm)
Signs and symptoms of total body exposure to radiation, most conspicuous with respect to the system most affected.
References in periodicals archive ?
Her research has spanned drug discovery, preclinical development, manufacturing and clinical development in indications such as acute radiation syndrome, inflammation, infectious disease, cancer and cancer supportive care.
Soligenix is also developing OrbeShield(TM) for the treatment of gastrointestinal acute radiation syndrome (GI ARS) under a BARDA contract award valued up to $26.
Maxygen submitted a white paper entitled Development of MAXY-G34 as a Medical Countermeasure for Acute Radiation Syndrome in December 2010 in response to a Broad Agency Announcement (BAA-10-100-SOL-00012).
The contract is for the advanced preclinical and manufacturing development of OrbeShield(TM) (oral beclomethasone 17,21-dipropionate or oral BDP) as a MCM for the treatment of gastrointestinal acute radiation syndrome (GI ARS).
WASHINGTON -- The development of five new drugs to treat injuries associated with acute radiation syndrome will move forward under contracts awarded by the U.
OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that the Office of Orphan Products Development of the US Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient SGX94 for the treatment of acute radiation syndrome (ARS).
7 million by the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response of the Department of Health and Human Services, for the advanced development of CLT-008, a first-in-class, allogeneic, cell-based therapy for the treatment of Acute Radiation Syndrome (ARS).
In response to an invitation from the Biomedical Advanced Research and Development Authority (BARDA), we submitted a contract proposal to support the development of OrbeShield (TM) for the treatment of gastrointestinal acute radiation syndrome (GI ARS), which if awarded, has the potential to be a multi-million dollar contract.
New contracts fund drugs to treat gastrointestinal tract injuries of acute radiation syndrome
This submission supports a potential multi-year, multi-million dollar contract to develop OrbeShield (TM)(oral beclomethasone 17,21-dipropionate or oral BDP) as a medical countermeasure (MCM) for the treatment of gastrointestinal acute radiation syndrome (GI ARS).
OTCQB: SNGX)(Soligenix or the Company), a development stage biopharmaceutical company, announced today that pursuant to review of the Company's white paper on development of OrbeShield (TM) as a countermeasure for the gastrointestinal effects of acute radiation syndrome (GI ARS), the Biomedical Advanced Research and Development Authority (BARDA), Division of Chemical, Biological, Radiological and Nuclear (CBRN) Medical Countermeasures has informed the Company that after careful analysis and consideration, it is inviting Soligenix to submit a full proposal for a potential multi-year, multi-million dollar contract to develop OrbeShield (TM) from its current level of technical readiness to FDA approval.
Nasdaq:MAXY) today announced that it has submitted a proposal to the Biomedical Advanced Research and Development Authority (BARDA) for a multi-year, multi-million dollar contract for the development of its MAXY-G34 product candidate as a potential medical countermeasure for Acute Radiation Syndrome (ARS).